ATXI — Avenue Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.27m
- -$0.67m
- $1.40m
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Avenue Therapeutics Inc expected to post a loss of 94 cents a share - Earnings Preview
Avenue Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ciena, Huntsman, Prog Holdings
Brief: Avenue Therapeutics Received Notice From Nasdaq Notifying Co Is In Compliance With All Requirement Set Forth In Nasdaq Listing Rule 5550(B)(1)
Brief: Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Brief: Avenue Therapeutics May Offer Shares Of Common Stock Having Offering Price Of Up To $3.9 Mln
Avenue Therapeutics Inc expected to post a loss of $9.00 a share - Earnings Preview
Brief: Avenue Therapeutics Announces Reverse Stock Split
Brief: Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
U.S. STOCKS ON THE MOVE-Boeing, Equitrans Midstream, Crypto-linked stocks
U.S. STOCKS ON THE MOVE-Crypto stocks, US insurers, EPAM Systems
U.S. STOCKS ON THE MOVE-Apple, Lamb Weston, Dyne Therapeutics
Avenue Therapeutics jumps on finalizing pain relief drug's study design with FDA
Brief: Avenue Therapeutics Inc - REACHES FINAL AGREEMENT WITH THE U.S. FDA FOR THE PHASE 3 SAFETY STUDY
Brief: Robert Davidow Reports 14.5 % Passive Stake In Avenue Therapeutics